Crescent Biopharma Inc - Company Profile
Powered by 
All the sales intelligence you need on Crescent Biopharma Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Crescent Biopharma Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Crescent Biopharma Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Crescent Biopharma Inc (Crescent Biopharma), formerly GlycoMimetics Inc, is a clinical-stage biotechnology company focused on developing transformative therapies for cancer treatment. The company's main activities involve the identification and development of innovative oncology therapeutics. Crescent Biopharma's major product in development is CR-001, a PD-1 x VEGF bispecific antibody designed to target both the PD-1 immune checkpoint and Vascular Endothelial Growth Factor. The company is also building a portfolio of potentially best-in-class antibody-drug conjugates (ADCs). Crescent Biopharma's products are aimed at treating solid tumors, with applications in the healthcare industry. The company is in the early stage of development and commercialization SKB105 (CR-003). Crescent Biopharma is headquartered in Waltham, Massachusetts, the US.
Headquarters
United States of America
Address
300 Fifth Avenue, Waltham, Massachusetts, 02451
Website
www.crescentbiopharma.com
Telephone
1 617 4305595
No of Employees
44
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CBIO (NASD)
Revenue (2024)
$10.8M
EPS
XYZ
Net Income (2024)
XYZ
-311.7%
(2024 vs 2023)
Market Cap*
$643.7M
Net Profit Margin (2024)
XYZ
97.7%
(2024 vs 2023)
* As of and is in US$
Crescent Biopharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| CR-001: PD-1 and VEGF in solid tumors |
| CR-002: PD-L1 in cancer cells |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In December, the company entered into a License Agreement with Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, to research, develop, manufacture, and commercialize CR-001 in Greater China. |
| 2025 | Acquisitions/Mergers/Takeovers | In June, the company merged with Crescent Biopharma, a biotech company and renamed itself as Crescent Biopharma Inc. |
| 2021 | Regulatory Approval | In January, the company’s APL-106 (uproleselan) has been granted Breakthrough Therapy Designation from the China National Medical Products Administration Center for Drug Evaluation for the treatment of acute myeloid leukemia. |
Competitor Comparison
| Key Parameters | Crescent Biopharma Inc | BioNTech SE | ImmunityBio Inc | Kura Oncology Inc | Instil Bio Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | United States of America | United States of America | United States of America |
| City | Waltham | Mainz | San Diego | San Diego | Dallas |
| State/Province | Massachusetts | Rheinland-Pfalz | California | California | Texas |
| No. of Employees | 44 | 7,807 | 691 | 260 | 17 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Joshua Brumm | Director; Chief Executive Officer | Executive Board | 2025 | 48 |
| Richard Scalzo | Chief Financial Officer | Senior Management | 2025 | 39 |
| Jonathan McNeill | Chief Operating Officer; President | Senior Management | 2025 | 40 |
| Ellie Im | Chief Medical Officer | Senior Management | 2025 | 48 |
| Jan Pinkas | Chief Scientific Officer | Senior Management | 2025 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer